BRKR at a glance
Bruker Corp (BRKR, SEC CIK 1109354) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Bruker Corp (BRKR) shares worth $2.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Munch Mark on September 15, 2026 of 2,000 shares at $52.87 per share.
- In the last 90 days, BRKR insiders reported 0 open-market purchases ($0) and 1 open-market sale ($106K) on Form 4, a net sale of $106K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.4B
- +2.1% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$106K
- 13F holders
- 34 funds
- $2.9B · +1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 8.01 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors from the 2025 Form 10-K
- Business performance remains exposed to previously disclosed risks affecting financial condition and operating results
- Additional unknown or currently immaterial risks could materially adversely affect results
Management Discussion & Analysis
- Q3 revenue $874.0M, up 1.6% YoY from $860.5M
- GAAP gross margin 49.1% vs 44.1%; operating margin (10.4)% vs (6.0)%
- BEST strongest growth, revenue $82.1M, up 11.2%; BSI NANO weakest, revenue $263.1M, down 1.3%
- Operating cash flow $118.2M vs $(33.2)M; nine-month free cash flow $37.5M vs $(163.9)M
- Outlook: cash and facilities sufficient for at least twelve months; tariffs and trade uncertainty threaten bookings, revenue and profitability
AI summary of the BRKR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Quarterly cash dividend: $0.05 per common share
- Payable January 7, 2027, to shareholders of record December 21, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expansion from 11 to 12 directors, increasing governance capacity
- Eicke Latz MD PhD joins effective January 1, 2027, serving Class II through the 2029 Annual Meeting
Item EX-99.1: Item EX-99.1
- Dr. Eicke Latz joining Bruker’s board effective January 1, 2027
- Scientific leadership in innate immunity, inflammation, proteomics, and molecular diagnostics
Item 8.01: Other Events
- Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments
- BSI BIOS expanded to include BioSpin, SciY, CST, Daltonics, Optics and Mimetas
Item EX-99.1: Item EX-99.1
- Segment recast separates BioSpin into BIOS and BMID, improving comparability of operating performance
- Six-month 2026 revenue $1,661.9M, up from $1,598.8M in 2025
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Press release in Exhibit 99.1 contains the substantive financial figures and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $874.0M, up 1.6% YoY, but organic growth only 0.7%, signaling modest underlying demand
- Non-GAAP operating margin expanded to 16.3% from 12.3%, while non-GAAP EPS rose 24.4% to $0.56
AI summaries of BRKR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BRKR
Don't miss the next BRKR filing
- Alerts as it files. A push when BRKR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BRKR, by share count.
- Ask anything. An AI agent that reads every BRKR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Munch Mark | M | Sep 15, 2026 | 2,000 | - |
| Munch Mark | Sell | Sep 15, 2026 | 2,000 | $52.87 |
| Munch Mark | M | Sep 15, 2026 | 2,000 | $22.19 |
| Pusch Wolfgang | Sell | Aug 17, 2026 | 3,473 | $56.90 |
| Srega Juergen | A | Aug 15, 2026 | 16,898 | - |
| Prause Burkhard | A | Aug 15, 2026 | 2,678 | - |
| Munch Mark | F | Aug 15, 2026 | 2,984 | $57.70 |
| Srega Juergen | A | Aug 15, 2026 | 13,698 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.4B | $3.4B |
| Gross Profit | - | $1.6B | $1.6B |
| Operating Income | - | $253.1M | $68.2M |
| Net Income | - | $113.1M | -$8.6M |
| Gross Margin | - | 49.0% | 45.9% |
| Op. Margin | - | 7.5% | 2.0% |
| Net Margin | - | 3.4% | -0.3% |
| Balance Sheet | |||
| Total Assets | $4.2B | $5.8B | $6.2B |
| Equity | $1.4B | $1.8B | $2.5B |
| ROE | - | 6.3% | -0.4% |
| Per Share | |||
| EPS | - | $0.76 | $-0.15 |
| Cash Flow | |||
| Operating CF | - | $251.3M | $134.1M |
| CapEx | - | $115.3M | $90.8M |
Source: XBRL data in Bruker Corp (BRKR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BRKR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $2.90B |
| Q2 2026 | 33 | $3.92B |
| Q1 2026 | 33 | $2.16B |
| Q4 2025 | 29 | $2.62B |
| Q3 2025 | 30 | $1.71B |
| Q2 2025 | 31 | $2.17B |
| Q1 2025 | 29 | $1.75B |
| Q4 2024 | 23 | $2.15B |
- T. Rowe Price Group+1.23M (+50%)
- AQR Capital Management+557.6K (+22%)
- Bridgewater Associates LP+445.5K (+1052%)
- BlackRock+382.1K (+3%)
- Vanguard Portfolio Management LLC+86.6K (+2%)
- Franklin Resources−1.04M (-32%)
- Goldman Sachs Group−532.5K (-47%)
- Citadel Advisors LLC−171.3K (-96%)
- Wells Fargo & Co−121.0K (-56%)
- Two Sigma Investments−96.9K (-86%)
- Millennium Management+106.7K
- Citizens Financial Group+6.4K
- Marex Group plc+4.1K
- FMR LLC (Fidelity)−20.24M
- Viking Global Investors−893.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 242 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BRKR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
BRKR SEC filings: frequently asked questions
Are BRKR insiders buying or selling?
In the last 90 days, Bruker Corp (BRKR) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $105,740 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BRKR stock?
As of September 30, 2026, the largest Bruker Corp (BRKR) holders among the 13F filers tracked by SignalX were BlackRock ($763.4 million), Vanguard Portfolio Management LLC ($322.1 million), Vanguard Capital Management LLC ($314.7 million), State Street Corp ($259.4 million), T. Rowe Price Group ($238.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BRKR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15. The figures come from the XBRL data in the 10-K.
What did BRKR report in its latest 8-K?
Bruker Corp (BRKR) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Quarterly cash dividend: $0.05 per common share.
What are the latest BRKR SEC filings?
Bruker Corp (BRKR) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 16, 2026.
What is BRKR's SEC CIK number?
Bruker Corp (BRKR)'s SEC Central Index Key (CIK) is 1109354. EDGAR lists every BRKR filing under that number.
Ask anything about BRKR
The research agent reads BRKR's filings, financials, insider trades and 13F holders, then answers with sources.